Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(1.25%)
AUD 0.08
(1.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -7.19 Million AUD | -11.68% |
| 2023 | -9.68 Million AUD | -27.5% |
| 2022 | -7.59 Million AUD | -102.31% |
| 2021 | -3.75 Million AUD | 5.62% |
| 2020 | -3.97 Million AUD | -71.52% |
| 2019 | -2.31 Million AUD | 61.63% |
| 2018 | -6.04 Million AUD | -234.34% |
| 2017 | -1.8 Million AUD | 35.32% |
| 2016 | -2.79 Million AUD | 28.1% |
| 2015 | -3.88 Million AUD | -90.73% |
| 2014 | -2.03 Million AUD | -18.1% |
| 2013 | -1.72 Million AUD | -8.02% |
| 2012 | -1.59 Million AUD | 43.89% |
| 2011 | -2.84 Million AUD | -39.44% |
| 2010 | -2.04 Million AUD | 13.99% |
| 2009 | -2.37 Million AUD | 18.55% |
| 2008 | -2.91 Million AUD | -104.17% |
| 2007 | -1.42 Million AUD | -22198.84% |
| 2006 | -6399.00 AUD | 99.63% |
| 2005 | -1.74 Million AUD | -99.31% |
| 2004 | -874.9 Thousand AUD | 16.16% |
| 2003 | -1.04 Million AUD | -39.08% |
| 2002 | -750.34 Thousand AUD | -766.95% |
| 2001 | -86.55 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.95 Million AUD | -196.19% |
| 2024 Q3 | -2.01 Million AUD | 66.2% |
| 2024 FY | -10.81 Million AUD | -11.68% |
| 2024 Q4 | -2.01 Million AUD | 0.0% |
| 2024 Q1 | -2.01 Million AUD | 57.69% |
| 2023 Q3 | -2.37 Million AUD | 51.73% |
| 2023 Q2 | -4.92 Million AUD | -154.1% |
| 2023 Q1 | -1.93 Million AUD | 49.36% |
| 2023 FY | -9.68 Million AUD | -27.5% |
| 2023 Q4 | -4.75 Million AUD | -100.0% |
| 2022 Q3 | -1.91 Million AUD | 49.21% |
| 2022 Q4 | -3.82 Million AUD | -100.0% |
| 2022 FY | -7.59 Million AUD | -102.31% |
| 2022 Q1 | -1.88 Million AUD | 31.24% |
| 2022 Q2 | -3.76 Million AUD | -100.0% |
| 2021 Q2 | -1.94 Million AUD | -111.87% |
| 2021 Q3 | -1.05 Million AUD | 45.66% |
| 2021 Q4 | -2.74 Million AUD | -158.88% |
| 2021 FY | -3.75 Million AUD | 5.62% |
| 2021 Q1 | -919.3 Thousand AUD | 64.54% |
| 2020 FY | -3.97 Million AUD | -71.52% |
| 2020 Q2 | -2.22 Million AUD | -101.21% |
| 2020 Q1 | -1.1 Million AUD | 30.12% |
| 2020 Q3 | -1.27 Million AUD | 42.88% |
| 2020 Q4 | -2.59 Million AUD | -103.89% |
| 2019 Q3 | -791.65 Thousand AUD | -106.78% |
| 2019 Q2 | -382.85 Thousand AUD | 0.0% |
| 2019 Q1 | -382.85 Thousand AUD | 42.15% |
| 2019 Q4 | -1.58 Million AUD | -100.0% |
| 2019 FY | -2.31 Million AUD | 61.63% |
| 2018 Q4 | -661.78 Thousand AUD | -0.38% |
| 2018 Q2 | -1.07 Million AUD | 0.0% |
| 2018 FY | -6.04 Million AUD | -234.34% |
| 2018 Q1 | -1.07 Million AUD | -108.73% |
| 2018 Q3 | -659.26 Thousand AUD | 38.8% |
| 2017 Q4 | -516.07 Thousand AUD | -22.25% |
| 2017 FY | -1.8 Million AUD | 35.32% |
| 2017 Q3 | -422.15 Thousand AUD | 16.55% |
| 2017 Q2 | -505.88 Thousand AUD | 0.0% |
| 2017 Q1 | -505.88 Thousand AUD | 16.02% |
| 2016 Q1 | -862.06 Thousand AUD | 9.58% |
| 2016 FY | -2.79 Million AUD | 28.1% |
| 2016 Q4 | -602.4 Thousand AUD | 0.0% |
| 2016 Q2 | -862.06 Thousand AUD | 0.0% |
| 2016 Q3 | -602.4 Thousand AUD | 30.12% |
| 2015 FY | -3.88 Million AUD | -90.73% |
| 2015 Q4 | -953.44 Thousand AUD | 0.0% |
| 2015 Q3 | -953.44 Thousand AUD | 1.71% |
| 2015 Q2 | -969.99 Thousand AUD | 0.0% |
| 2015 Q1 | -969.99 Thousand AUD | -19.44% |
| 2014 Q2 | -135 Thousand AUD | 0.0% |
| 2014 Q1 | -135 Thousand AUD | 68.11% |
| 2014 FY | -2.03 Million AUD | -18.1% |
| 2014 Q4 | -812.14 Thousand AUD | 0.0% |
| 2014 Q3 | -812.14 Thousand AUD | -501.57% |
| 2013 Q1 | -465.83 Thousand AUD | 0.0% |
| 2013 Q3 | -423.39 Thousand AUD | 9.11% |
| 2013 Q4 | -423.39 Thousand AUD | 0.0% |
| 2013 FY | -1.72 Million AUD | -8.02% |
| 2013 Q2 | -465.83 Thousand AUD | 0.0% |
| 2012 FY | -1.59 Million AUD | 43.89% |
| 2011 FY | -2.84 Million AUD | -39.44% |
| 2010 FY | -2.04 Million AUD | 13.99% |
| 2009 FY | -2.37 Million AUD | 18.55% |
| 2008 FY | -2.91 Million AUD | -104.17% |
| 2007 FY | -1.42 Million AUD | -22198.84% |
| 2006 FY | -6399.00 AUD | 99.63% |
| 2005 FY | -1.74 Million AUD | -99.31% |
| 2004 FY | -874.9 Thousand AUD | 16.16% |
| 2003 FY | -1.04 Million AUD | -39.08% |
| 2002 FY | -750.34 Thousand AUD | -766.95% |
| 2001 FY | -86.55 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -36.709% |
| Acrux Limited | -9.83 Million AUD | 26.855% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 51.067% |
| BTC Health Limited | 1.05 Million AUD | 781.62% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 41.566% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 83.944% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 114.635% |
| Biome Australia Limited | -1.91 Million AUD | -275.962% |
| Hexima Limited | -1 Million AUD | -613.065% |
| Immutep Limited | -44.93 Million AUD | 83.993% |
| Memphasys Limited | -2.7 Million AUD | -166.015% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 103.183% |
| Noxopharm Limited | -7.53 Million AUD | 4.538% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -0.092% |
| Race Oncology Limited | -13.38 Million AUD | 46.243% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 84.764% |
| Starpharma Holdings Limited | -15.15 Million AUD | 52.549% |
| Tissue Repair Ltd | -4.87 Million AUD | -47.521% |
| Biotron Limited | -5.15 Million AUD | -39.639% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 63.304% |
| CSL Limited | 5.64 Billion AUD | 100.127% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 174.029% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -392.969% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -134.878% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -21.131% |
| Patrys Limited | -3.53 Million AUD | -103.242% |
| Orthocell Limited | -11.68 Million AUD | 38.422% |
| Imugene Limited | -140.93 Million AUD | 94.896% |
| PYC Therapeutics Limited | -38.85 Million AUD | 81.489% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 0.532% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 18.334% |
| Nanollose Limited | -1.24 Million AUD | -475.524% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -237.128% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -249.761% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -62.556% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -150.299% |
| Nyrada Inc. | -4.56 Million AUD | -57.731% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 71.296% |
| PharmAust Limited | -6.65 Million AUD | -8.026% |
| AnteoTech Limited | -11.72 Million AUD | 38.66% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 88.953% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 67.38% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -56.739% |
| Actinogen Medical Limited | -12.83 Million AUD | 43.975% |
| Immuron Limited | -5.8 Million AUD | -23.994% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -26.835% |